Geneva, June 16 -- International Clinical Trials Registry received information related to the study (NCT07005284) titled 'A Study of LY3981314 in Healthy Participants' on June 3.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator).

Primary Sponsor: Eli Lilly and Company

Condition: Healthy

Intervention: Drug: LY3981314

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: June 2025

Target Sample Size: 76

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07005284

Published by HT Digital Content Services with permission from ...